These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8852401)

  • 1. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
    Ragnhammar P; Blomgren H
    Med Oncol; 1995 Sep; 12(3):187-201. PubMed ID: 8852401
    [No Abstract]   [Full Text] [Related]  

  • 2. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
    Köhne CH; Wilke H; Schöffski P; Schmoll HJ
    J Infus Chemother; 1996; 6(4):206-10. PubMed ID: 9229317
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trials referral resource. Treatment of advanced colorectal cancer.
    Cheson BD
    Oncology (Williston Park); 1991 Apr; 5(4):61-2, 65-6, 68 passim. PubMed ID: 1831041
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
    Köhne-Wömpner CH; Schmoll HJ; Harstrick A; Rustum YM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
    Kemeny NE; Schneider A; Martin DS
    Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ
    Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B; Luis R; Jaime M; Franceschi D
    Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Where do we stand with 5-fluorouracil?
    Schmoll HJ; Büchele T; Grothey A; Dempke W
    Semin Oncol; 1999 Dec; 26(6):589-605. PubMed ID: 10606252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of advanced cancer of the colon and rectum.
    Bruckner HW; Motwani BT
    Semin Oncol; 1991 Oct; 18(5):443-61. PubMed ID: 1925632
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical modulation: a modality that has come of therapeutic age.
    Allegra CJ
    J Clin Oncol; 1991 Oct; 9(10):1723-6. PubMed ID: 1919622
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent advances in the treatment of advanced colorectal cancer.
    Kemeny N; Lokich JJ; Anderson N; Ahlgren JD
    Cancer; 1993 Jan; 71(1):9-18. PubMed ID: 8416731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparfosate. A novel biomodulator of 5-fluorouracil.
    Koshland P; Maa L; Ignoffo R
    Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer chemotherapy: past is prologue.
    Martin DS
    Mt Sinai J Med; 1985 Jun; 52(6):426-34. PubMed ID: 3875021
    [No Abstract]   [Full Text] [Related]  

  • 15. Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
    Punt CJ; Kamm YL; Wagener DJ
    Anticancer Drugs; 1997 Jun; 8(5):454-8. PubMed ID: 9215607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
    J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
    Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
    Leonard GD; Kemeny NE
    Dis Colon Rectum; 2006 Mar; 49(3):407-10. PubMed ID: 16475032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D
    Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B
    Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.